Dr. Brawer on Predicting Radical Prostatectomy Outcomes

Video

Michael Brawer, MD, vice president, Medical Affairs, Myriad Genetics, discusses a study that looked at predicting radical prostatectomy outcomes.

Michael Brawer, MD, vice president, Medical Affairs, Myriad Genetics, discusses a study that looked at predicting radical prostatectomy outcomes.

This study looked to answer the question as to whether grade is as important of a predictive tool as it has been in the past. Patients with gleason score (GS) <7 were analyzed. Their initial GS were compared with their score on radical prostatectomy.

The results of this study indicate that the risk of biochemical recurrence is indistinguishable in men with GS <7 who have pathologic GS 3+4 or 4+3. The Prolaris test does provide stratification of this risk.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD